Mogamulizumab for the Treatment of HTLV-1–Associated Myelopathy

Mogamulizumab was relatively safe and showed possible benefit for the treatment of tropical spastic paraparesis in a long-term, open-label extension study.

Human T-cell leukemia virus type 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) is caused by a chronic inflammation triggered by infiltration of HTLV-1–infected cells in the spinal cord, eventually resulting in spastic paraparesis, bladder and bowel dysfunction, and sensory symptoms. HAM/TSP is caused by a retrovirus that primarily infects CD4⁺ T cells. Treatments to date have not been effective enough and have caused severe side effects.

This open-label, long-term study was conducted following a phase 1–2a trial with mogamulizumab, an antibody against C-C motif chemokine receptor 4 (CCR4) that is FDA-approved for other conditions. For this study, outcomes were assessed throughout four years of mogamulizumab treatmen…

Reviewing Author

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders

Mogamulizumab for the Treatment of HTLV-1–Associated Myelopathy

Topics

Reviewing Author